NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

$1.43
-0.10 (-6.54%)
(As of 05/17/2024 ET)
Today's Range
$1.42
$1.58
50-Day Range
$1.43
$12.62
52-Week Range
$1.42
$14.75
Volume
119,558 shs
Average Volume
171,139 shs
Market Capitalization
$3.83 million
P/E Ratio
2.13
Dividend Yield
N/A
Price Target
$60.00

TRACON Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
4,095.8% Upside
$60.00 Price Target
Short Interest
Bearish
7.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.10mentions of TRACON Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.00) to ($5.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.29 out of 5 stars

TCON stock logo

About TRACON Pharmaceuticals Stock (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

TCON Stock Price History

TCON Stock News Headlines

Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
TRACON Pharmaceuticals Inc
TRACON announces 1-for-20 reverse stock split
TRACON Pharmaceuticals Announces Reverse Stock Split
See More Headlines
Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
5/19/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TCON
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.00
High Stock Price Target
$60.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+4,095.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-3,590,000.00
Pretax Margin
13.98%

Debt

Sales & Book Value

Annual Sales
$12.05 million
Cash Flow
$1.59 per share
Book Value
($0.66) per share

Miscellaneous

Free Float
2,538,000
Market Cap
$3.83 million
Optionable
No Data
Beta
1.28
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Charles P. Theuer M.D. (Age 60)
    Ph.D., Chairman, CEO & President
    Comp: $646.6k
  • Mr. Ya Huang
    Executive Director of Statistical Programming

TCON Stock Analysis - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TCON shares.
View TCON analyst ratings
or view top-rated stocks.

What is TRACON Pharmaceuticals' stock price target for 2024?

3 analysts have issued 1 year target prices for TRACON Pharmaceuticals' stock. Their TCON share price targets range from $60.00 to $60.00. On average, they anticipate the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 4,095.8% from the stock's current price.
View analysts price targets for TCON
or view top-rated stocks among Wall Street analysts.

How have TCON shares performed in 2024?

TRACON Pharmaceuticals' stock was trading at $3.5020 at the start of the year. Since then, TCON shares have decreased by 59.2% and is now trading at $1.43.
View the best growth stocks for 2024 here
.

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our TCON earnings forecast
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) issued its quarterly earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.13. The biopharmaceutical company earned $0.10 million during the quarter. During the same quarter in the prior year, the business posted ($7.20) EPS.

When did TRACON Pharmaceuticals' stock split?

Shares of TRACON Pharmaceuticals reverse split on Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCON) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners